Analysis Of Income And Expense [Abstract]

Tchaikapharma High Quality Medicines AD - Filing #6023734

Concept 2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
42 431 BGN
40 105 BGN
Expenses by nature [abstract]
Raw materials and consumables used
15 583 BGN
14 320 BGN
Cost of merchandise sold
1 105 BGN
817,000 BGN
Services expense
15 097 BGN
14 085 BGN
Classes of employee benefits expense [abstract]
Employee benefits expense
5 680 BGN
4 960 BGN
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Depreciation and amortisation expense [abstract]
Depreciation and amortisation expense
3 877 BGN
4 231 BGN
Impairment loss (reversal of impairment loss) recognised in profit or loss
- BGN
50,000 BGN
Other expenses, by nature
776,000 BGN
602,000 BGN
Disclosure of attribution of expenses by nature to their function [text block]
Disclosure of attribution of expenses by nature to their function [abstract]
Disclosure of attribution of expenses by nature to their function [line items]
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
- BGN
- BGN
287,000 BGN
- BGN
1 683 BGN
1 683 BGN
1 396 BGN
604,000 BGN
- BGN
593,000 BGN
- BGN
593,000 BGN
11,000 BGN
- BGN
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent
1 683 BGN
593,000 BGN
Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract]
Comprehensive income, attributable to non-controlling interests
- BGN
- BGN

Talk to a Data Expert

Have a question? We'll get back to you promptly.